Document is current
Any future updates will be listed below
-
Authors
Han, Yuchi https://orcid.org/0000-0001-7582-1848
Forfia, Paul R
Vaidya, Anjali
Mazurek, Jeremy A
Park, Myung H
Ramani, Gautam
Chan, Stephen Y
Waxman, Aaron B
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct02829034 at ClinicalTrials.govnct01757808 at ClinicalTrials.govDocuments that mention this clinical trial
Rationale and design of the ranolazine PH–RV study: a multicentred randomised and placebo-controlled study of ranolazine to improve RV function in patients with non-group 2 pulmonary hypertension
https://doi.org/10.1136/openhrt-2017-000736
nct01174173 at ClinicalTrials.govDocuments that mention this clinical trial
Rationale and design of the ranolazine PH–RV study: a multicentred randomised and placebo-controlled study of ranolazine to improve RV function in patients with non-group 2 pulmonary hypertension
https://doi.org/10.1136/openhrt-2017-000736
nct02133352 at ClinicalTrials.govDocuments that mention this clinical trial
Rationale and design of the ranolazine PH–RV study: a multicentred randomised and placebo-controlled study of ranolazine to improve RV function in patients with non-group 2 pulmonary hypertension
https://doi.org/10.1136/openhrt-2017-000736
nct01839110 at ClinicalTrials.govDocuments that mention this clinical trial
Rationale and design of the ranolazine PH–RV study: a multicentred randomised and placebo-controlled study of ranolazine to improve RV function in patients with non-group 2 pulmonary hypertension
https://doi.org/10.1136/openhrt-2017-000736
nct02829034 at ClinicalTrials.govDocuments that mention this clinical trial
Rationale and design of the ranolazine PH–RV study: a multicentred randomised and placebo-controlled study of ranolazine to improve RV function in patients with non-group 2 pulmonary hypertension
https://doi.org/10.1136/openhrt-2017-000736
Documents that mention this clinical trial
Rationale and design of the ranolazine PH–RV study: a multicentred randomised and placebo-controlled study of ranolazine to improve RV function in patients with non-group 2 pulmonary hypertension
https://doi.org/10.1136/openhrt-2017-000736
-
Funding
Funding for this research was provided by:
Cardiovascular Medical Research and Education Fund
Gilead Sciences
